Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

di McTigue, Michele, Murray, Brion William, Chen, Jeffrey H., Deng, Ya-Li, Solowiej, James, Kania, Robert S.
Pubblicazione 2012

Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design

di Chen, Ping, Deng, Ya-Li, Bergqvist, Simon, Falk, Matthew D, Liu, Wei, Timofeevski, Sergei, Brooun, Alexei
Pubblicato in Protein Sci (2014)

High molecular weight chitosan derivative polymeric micelles encapsulating superparamagnetic iron oxide for tumor-targeted magnetic resonance imaging

di Xiao, Yunbin, Lin, Zuan Tao, Chen, Yanmei, Wang, He, Deng, Ya Li, Le, D Elizabeth, Bin, Jianguo, Li, Meiyu, Liao, Yulin, Liu, Yili, Jiang, Gangbiao, Bin, Jianping
Pubblicato in Int J Nanomedicine (2015)

Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein–protein interaction

di Cardoso, Rosa, Love, Robert, Nilsson, Carol L, Bergqvist, Simon, Nowlin, Dawn, Yan, Jiangli, Liu, Kevin K-C, Zhu, Jing, Chen, Ping, Deng, Ya-Li, Dyson, H Jane, Greig, Michael J, Brooun, Alexei
Pubblicazione 2012

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

di Brooun, Alexei, Gajiwala, Ketan S., Deng, Ya-Li, Liu, Wei, Bolaños, Ben, Bingham, Patrick, He, You-Ai, Diehl, Wade, Grable, Nicole, Kung, Pei-Pei, Sutton, Scott, Maegley, Karen A., Yu, Xiu, Stewart, Al E.
Pubblicato in Nat Commun (2016)

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

di Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Pubblicazione 2013

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

di Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, Fantin, Valeria R.
Pubblicato in Proc Natl Acad Sci U S A (2015)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

di Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Pubblicato in N Engl J Med (2015)

Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library

di Kung, Pei-Pei, Bingham, Patrick, Burke, Benjamin J., Chen, Qiuxia, Cheng, Xuemin, Deng, Ya-Li, Dou, Dengfeng, Feng, Junli, Gallego, Gary M., Gehring, Michael R., Grant, Stephan K., Greasley, Samantha, Harris, Anthony R., Maegley, Karen A., Meier, Jordan, Meng, Xiaoyun, Montano, Jose L., Morgan, Barry A., Naughton, Brigitte S., Palde, Prakash B., Paul, Thomas A., Richardson, Paul, Sakata, Sylvie, Shaginian, Alex, Sonnenburg, William K., Subramanyam, Chakrapani, Timofeevski, Sergei, Wan, Jinqiao, Yan, Wen, Stewart, Albert E.
Pubblicato in ACS Med Chem Lett (2020)